Michael R. Lebens

Family Medicine
325 Posada Ln
Templeton, CA 93465

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.

Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.

Journal: Vaccines
Published: May 06, 2026

Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection.

Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection.

Journal: Nature communications
Published: October 06, 2024

Cholera intoxication of human enteroids reveals interplay between decoy and functional glycoconjugate ligands.

Cholera intoxication of human enteroids reveals interplay between decoy and functional glycoconjugate ligands.

Journal: Glycobiology
Published: March 10, 2023

A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.

A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.

Journal: Vaccine
Published: December 23, 2022

Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years.

Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years.

Journal: Travel medicine and infectious disease
Published: December 21, 2021

Characterization of the ganglioside recognition profile of Escherichia coli heat-labile enterotoxin LT-IIc.

Characterization of the ganglioside recognition profile of Escherichia coli heat-labile enterotoxin LT-IIc.

Journal: Glycobiology
Published: October 22, 2021

A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.

A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.

Journal: Vaccine
Published: February 08, 2021

Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus.

Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus.

Journal: Vascular pharmacology
Published: August 19, 2020

Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.

Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.

Journal: Vaccine
Published: April 15, 2020

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.

Journal: Frontiers in immunology
Published: December 15, 2019

Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT.

Requirement for Cyclic AMP/Protein Kinase A-Dependent Canonical NFκB Signaling in the Adjuvant Action of Cholera Toxin and Its Non-toxic Derivative mmCT.

Journal: Frontiers in immunology
Published: November 27, 2018

Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity.

Proteomic analysis of cholera toxin adjuvant-stimulated human monocytes identifies Thrombospondin-1 and Integrin-β1 as strongly upregulated molecules involved in adjuvant activity.

Journal: Scientific reports
Published: August 10, 2018
Showing 1-12 of 28

Last Updated: 09/26/2026